PDF(Pubmed)
Abstract：
UNASSIGNED: It is unknown whether febuxostat can delay the progression of kidney dysfunction and reduce kidney endpoint events. The aim was to evaluate the renoprotective effect of febuxostat in patients with hyperuricemia or gout by performing a meta-analysis of randomized controlled trials (RCTs).
UNASSIGNED: MEDLINE, Web of science, EMBASE, ClinicalTrials.gov, and the Cochrane Central Register for Randomized Controlled Trials were searched. The main outcomes included kidney events (serum creatinine doubling or progression to end-stage kidney disease or dialysis). The secondary outcomes were the rate of change in the estimated glomerular filtration rate (eGFR) and changes in the urine protein or urine albumin to creatinine ratio from baseline to the end of follow-up. We used random-effects models to calculate the pooled risk estimates and 95% CIs.
UNASSIGNED: A total of 16 RCTs were included in the meta-analysis. In comparison with the control group, the patients who received febuxostat showed a reduced risk of kidney events (RR = 0.56, 95% CI 0.37-0.84, p = 0.006) and a slower decline in eGFR (WMD = 0.90 mL/min/1.73 m2, 95% CI 0.31-1.48, p = 0.003). The pooled results also revealed that febuxostat use reduced the urine albumin to creatinine ratio (SMD = -0.21, 95% CI -0.41 to -0.01, p = 0.042).
UNASSIGNED: Febuxostat use is associated with a reduced risk of kidney events and a slow decline in eGFR. In addition, the urine albumin to creatinine ratio decreased in febuxostat users. Accordingly, it is an effective drug for delaying the progression of kidney function deterioration in patients with gout.Systematic review registration: PROSPERO CRD42021272591.
UNASSIGNED: MEDLINE, Web of science, EMBASE, ClinicalTrials.gov, and the Cochrane Central Register for Randomized Controlled Trials were searched. The main outcomes included kidney events (serum creatinine doubling or progression to end-stage kidney disease or dialysis). The secondary outcomes were the rate of change in the estimated glomerular filtration rate (eGFR) and changes in the urine protein or urine albumin to creatinine ratio from baseline to the end of follow-up. We used random-effects models to calculate the pooled risk estimates and 95% CIs.
UNASSIGNED: A total of 16 RCTs were included in the meta-analysis. In comparison with the control group, the patients who received febuxostat showed a reduced risk of kidney events (RR = 0.56, 95% CI 0.37-0.84, p = 0.006) and a slower decline in eGFR (WMD = 0.90 mL/min/1.73 m2, 95% CI 0.31-1.48, p = 0.003). The pooled results also revealed that febuxostat use reduced the urine albumin to creatinine ratio (SMD = -0.21, 95% CI -0.41 to -0.01, p = 0.042).
UNASSIGNED: Febuxostat use is associated with a reduced risk of kidney events and a slow decline in eGFR. In addition, the urine albumin to creatinine ratio decreased in febuxostat users. Accordingly, it is an effective drug for delaying the progression of kidney function deterioration in patients with gout.Systematic review registration: PROSPERO CRD42021272591.
摘要：
■目前尚不清楚非布索坦是否可以延缓肾功能不全的进展并减少肾脏终点事件。目的是通过对随机对照试验（RCTs）进行荟萃分析，评估非布索坦对高尿酸血症或痛风患者的肾脏保护作用。
■MEDLINE,WebofScience,EMBASE,ClinicalTrials.gov,并检索了Cochrane中央注册中心的随机对照试验。主要结局包括肾脏事件（血清肌酐倍增或进展至终末期肾病或透析）。次要结果是估计肾小球滤过率（eGFR）的变化率以及从基线到随访结束的尿蛋白或尿白蛋白与肌酐比率的变化。我们使用随机效应模型来计算合并风险估计值和95%CI。
■共有16项随机对照试验纳入荟萃分析。与对照组相比，接受非布索坦治疗的患者肾脏事件风险降低(RR=0.56,95%CI0.37~0.84,p=0.006),eGFR下降较慢(WMD=0.90mL/min/1.73m2,95%CI0.31~1.48,p=0.003).合并的结果还显示，使用非布索坦降低了尿白蛋白与肌酐的比率（SMD=-0.21，95％CI-0.41至-0.01，p=0.042）。
非布索坦的使用与肾脏事件风险降低和eGFR缓慢下降相关。此外,非布索坦使用者的尿白蛋白与肌酐比值下降.因此，是延缓痛风患者肾功能恶化进展的有效药物。系统审查注册：PROSPEROCRD42021272591。
■MEDLINE,WebofScience,EMBASE,ClinicalTrials.gov,并检索了Cochrane中央注册中心的随机对照试验。主要结局包括肾脏事件（血清肌酐倍增或进展至终末期肾病或透析）。次要结果是估计肾小球滤过率（eGFR）的变化率以及从基线到随访结束的尿蛋白或尿白蛋白与肌酐比率的变化。我们使用随机效应模型来计算合并风险估计值和95%CI。
■共有16项随机对照试验纳入荟萃分析。与对照组相比，接受非布索坦治疗的患者肾脏事件风险降低(RR=0.56,95%CI0.37~0.84,p=0.006),eGFR下降较慢(WMD=0.90mL/min/1.73m2,95%CI0.31~1.48,p=0.003).合并的结果还显示，使用非布索坦降低了尿白蛋白与肌酐的比率（SMD=-0.21，95％CI-0.41至-0.01，p=0.042）。
非布索坦的使用与肾脏事件风险降低和eGFR缓慢下降相关。此外,非布索坦使用者的尿白蛋白与肌酐比值下降.因此，是延缓痛风患者肾功能恶化进展的有效药物。系统审查注册：PROSPEROCRD42021272591。
